In this series, the frequency of mutations involving TP53, NOTCH1, SF3B1, ATM, and BIRC3 genes clearly reflects the nature of our patient cohort that included untreated CLL analyzed early during the natural history of the disease and comprising 80.5 % of Binet stage A cases. This evidence concerns the gene ATM and B-cell chronic lymphocytic leukemia.